Abstract. Manipulating acetylation status of key gene targets is likely to be crucial for effective cancer therapy. In this study, we utilized green tea catechins, epicatechin (EC), epigallocatechin (EGC) and epigallocatechin-3-gallate (EGCG) to examine the regulation of androgen receptor acetylation in androgen-dependent prostate cancer cells by histone acetyltransferase (HAT) activity. EC, EGC and EGCG induced prostate cancer cell death, suppressed agonist-dependent androgen receptor (AR) activation and AR-regulated gene transcription. These results demonstrated a similar tendency to HAT inhibitory activities; EGCG>EGC>EC. The strongest HAT inhibitor among them, EGCG (50 µM), downregulated AR acetylation and finally, AR protein translocation to nucleus from the cytoplasmic compartment was effectively inhibited in the presence of the agonist. These results suggest another mechanism to develop effective therapeutics based on green tea catechins.
Introduction
Catechins have been shown to have cancer chemopreventive effects against several types of cancer, including prostate cancer (1, 2) . Like epigallocatechin-3-gallate (EGCG), other major catechins, epicatechin (EC) and epigallocatechin (EGC), also suppress androgen-dependent cell growth (3); however, they do not induce effective suppression of androgen-independent cell growth. Recent epidemiological data have associated tea consumption with a reduced frequency of hormone related cancers, including prostate cancer, suggesting that green tea catechins may affect hormone receptors (4) . Androgen receptor (AR) is a hormone nuclear receptor that mediates androgen action in prostate cells (5) . AR plays a key role in prostate cancer cellular proliferation and normal prostate development induced by the androgen, dihydrotestosterone (6) . It has recently become clear that human prostate cancer development involves post-transcriptional modifications, such as acetylation and phosphorylation of the androgen receptor (7) . Histone acetyltransferase (HAT) is one of the histone modifier proteins that acetylates AR during prostate cancer cell growth (8) . AR is acetylated by p300, P/CAF, and TIP60, leading to the recruitment of co-regulators to the basal transcription machinery of AR target genes and growth properties of the receptors, in cultured cells and in vivo (7) .
We have previously reported that EGCG suppresses RelA acetylation through its potent anti-HAT activity (9) . Here, we show that the major catechins of green tea suppress AR acetylation through their anti-HAT activities, reducing prostate cancer cell growth. We demonstrate that catechins regulate androgen-mediated transcription in an androgendependent prostate cancer cell line, LNCaP. We also suggest possible mechanisms for catechin-induced cell death in androgen-dependent prostate cancer cells, which may aid in the development of effective chemopreventive therapeutics.
Materials and methods
Cell culture and reagents. Human LNCaP cells were maintained in RPMI-1640 (Gibco-BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco-BRL). Cells in 6-well plates were supplemented with fresh medium 2 h before transfection with 1.5 µg DNA, according to the manufacturer's protocol for effective transfection (Qiagen).
EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity HAT, HDAC, HMT and SIRT1 activity assay. A HeLa cell nuclear extract (NE) was prepared as previously described (10). HAT activity and histone deacetylase (HDAC) activity assays were determined using a commercially available kit (Biovision Biotechnology, Mountain View, CA, USA) according to the manufacturer's instructions. Histone methyltransferase (HMT) activity assays were performed using the manufacturer's protocol as previously described (11) . For the HMT assay, core histone and assay buffer were from the HMT assay reagent kit (Upstate Biotechnology). Silent mating type information regulation 2 homologue (Sirtruin; SIRT) 1 activity was assayed with the CycLex SIRT1/Sir2 Deacetylase Fluorometric Assay kit (CycLex, Nagano, Japan).
Dual-luciferase assay. LNCaP cells were seeded at 5x10 5 cells/ well in 6-well culture plates and incubated overnight with RPMI-1640 containing 10% FBS. At 90% confluence, 0.5 µg of pGL3-PSA and 1 ng of pGL-5 SV40 per 6 wells were transfected into LNCaP cells to perform a dual luciferase assay (Promega). The medium was replaced with phenol redfree RPMI-1640 media containing 5% charcoal-stripped fetal bovine serum. After 48 h, 50 nM of the synthetic androgen R1881 treatment, 20 µM flutamide (Sigma-Aldrich) or EGCG (50 µM) was added. Cell were lysed and analyzed after 18 h by MicroLumat Plus (EG&G Berthold, Germany).
RNA extraction, real-time PCR analysis, and ChIP assays.
RNA extraction, real-time PCR, and ChIP were performed, as described (12) . The RT-PCR analysis and quantification was performed with SYBR-Green PCR Master Mix reagents on an ABI PRISM 7300 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The singularity and specificity of amplification were verified by a dissociation analysis software. All samples were normalized to human GAPDH. Primer sequences for amplification of NKX3-1 RNA were (F, 5'-CTGTCAGCCCCTGAACGG-3' and R, 5'-AACC ATATCTTCACTTGGGTCTCC-3'). Primer sequences for amplification of the PSA RNA were (F, 5'-AGTCTGAGGA GGTGTTCTGGTG-3' and R, 5'-GAGGTCGTGGCTGGA GTCATCA-3'). Primers used for ChIP analysis were: PSA (ARE1), 5'-TTGCATAAATTAGGGGAGAACATACCA-3' and 5'-GAGGGACCCAGCTGCGATTCA-3. All reactions were performed in triplicate. Relative expression levels and SDs were calculated using the comparative method.
Immunostaining. LNCaP cells were cultured in 2x2-cm 2 Lab-Tek chamber slides and the medium was replaced with phenol-free RPMI-1640 containing 10% charcoal-stripped FBS for 48 h. Cells were treated with EGCG and R1881 for 24 h, and then fixed with 4% formaldehyde at room temperature for 10 min. The fixed cells were rinsed with PBS and then stained with DAPI to detect nuclei and rhodamine-conjugated AR antibody. Cells were examined with the DeltaVision RT Imaging Microscope system (Applied Precision, Inc.).
Results
Major catechins induce anti-histone acetyltransferase activitydependent prostate cancer cell death. LNCaP, PC3 and HeLa cells were cultured with various concentrations of EC, EGC or EGCG for 2 days. As shown in Fig. 1A , EGCG, EGC and EC induced concentration-dependent cell death in the androgen-dependent prostate cancer, LNCaP cells, but in the androgen-independent prostate cancer cell, PC3, cell death by catechins did not dramatically increase compared to LNCaP cells (Fig. 1B) . In HeLa cells, catechins did not affect cell viability in any concentrations (Fig. 1C) . Since catechin derivatives have been known to possess anti-HAT activity (9), we next examined whether the differential effects of catechins on prostate cancer cell death is correlated with those of anti-HAT activities. Although EGCG, EGC and EC exhibited HAT inhibitory activities up to 70-90% at 100 µM, EGCG exhibited the highest anti-HAT activity among catechin derivatives ( Fig. 2A) . To assure that the inhibition of HAT activity was specific, we tested HDAC and HMT activities in cells treated with the same set of catechins. The results of these assays showed that none of the catechins affected HDAC or HMT activity (Fig. 2B and C) . To further confirm the enzyme specificity of catechins, we performed SIRT deacetylase assays using HeLa nuclear extract. Similar to the results of the HDAC and HMT assays, the SIRT deacetylase assay showed no difference either in the presence or absence of catechins (Fig. 2D) . Collectively, these results indicate that the selective suppression of androgen-dependent prostate cancer cell growth is positively correlated with the anti-HAT activities from catechins.
EGCG exhibits the highest inhibitory effects on androgenmediated transcription in LNCaP cells.
To measure the effects of EC, EGC and EGCG on AR-mediated transcription in LNCaP cells, we used an androgen-dependent reporter vector (pGL3-PSA) containing the androgen responsive element and the luciferase reporter gene. LNCaP cells were treated with a synthetic androgen, R1881, in the presence or absence of EC, EGC or EGCG (50 µM) for 48 h in RPMI-1640 containing charcoal-stripped FBS. Incubation with R1881 resulted in a dramatic increase in luciferase activity, whereas co-treatment with EGCG resulted in an 80% decrease in luciferase activity (Fig. 3A) . Consistent with the assays for cell death (Fig. 1A) and the specific anti-HAT activities of the individual catechins ( Fig. 2A) , EGCG had the highest inhibitory effects on R1881-bound AR-mediated transcription, followed by EGC and EC (EGCG > EGC > EC).
To determine whether EC, EGC and EGCG inhibition of AR-regulated gene expression is dose-dependent in LNCaP cells, the mRNA levels of endogeneous AR-regulated genes (PSA and NKX3.1) were measured by real-time PCR. LNCaP cells were exposed to 0, 50 or 100 µM of each catechin for 18 h, and total-RNA was then isolated. As expected, both an androgen-dependent increase and a catechin-induced reduction were observed in the mRNA levels of PSA and NKX3.1 (Fig. 3B) . EGCG treatment led to the most dramatic reduction of AR target gene expression at 50 and 100 µM. EGC and EC treatments led to significant reductions at 100 µM, but the effect was relatively weak compared to EGCG treatment.
Together, these studies indicate that EGCG exhibits the highest inhibitory effect on AR-mediated transcription and induction of prostate cancer cell death.
EGCG suppresses the p300-mediated histone and AR acetylation in LNCaP cells.
To confirm the relationship between anti-HAT activity and prostate cancer suppression, we measured the AR acetylation and the histone acetylation status of chromatin before and after treatment with EGCG. LNCaP cells were treated with R1881 or EGCG (50 µM), either individually or in combination for 24 h. First, to determine whether AR acetylation is affected by EGCG treatment in vivo, immunoprecipitation was performed on LNCaP cell lysate with a specific AR antibody and western blot analysis was subsequently used to determine the amount of acetylation at specific lysine residues. AR acetylation was increased in LNCaP cells in the presence of R1881, and this acetylation was decreased by EGCG treatment (Fig. 4A) . We then performed ChIP assays to observe histone acetylation and recruitment of p300 to the promoter region of the PSA gene. The R1881 treatment stimulated histone H3 acetylation and recruitment of p300 to PSA, however, EGCG suppressed the agonist-mediated recruitment of p300 to the promoter region (Fig. 4B) . Collectively, these results demonstrated that EGCG reduced the acetylation of AR and histones.
EGCG inhibits the p300-enhanced hormone responsiveness of AR and cellular proliferation. Since the overexpression of coactivators including p300 has been known to decrease the antagonist activities of flutamide and enhance the hormone responsiveness of AR, we next investigated the effect of EGCG treatment on antagonist-bound AR-mediated transcription. For this experiment, the transcription reporter plasmids, pSG5-p300 and pGL3-PSA, were transiently transfected into LNCaP cells (Fig. 5A) . As a positive control, AR activation by R1881 was abrogated by co-treatment with an androgen receptor inhibitor, flutamide (20 µM). Expression of p300 in LNCaP cells resulted in a 1.5-fold increase in luciferase activity with R1881 treatment compared to LNCaP cells with R1881 alone. EGCG treatment (50 µM) repressed transcription of the PSA reporter gene and prevented hyperacetylation of the AR receptor by p300 to a level similar to flutamide treatment, suggesting that EGCG inhibited p300-mediated PSA transcription. In the presence of ligand, AR translocates to the nucleus to access its target genes (13) . Therefore, to examine whether agonist-induced AR acetylation is a critical step for nuclear translocation of the AR, we next investigated the subcellular localization of AR with or without EGCG in LNCaP cells. For this experiment, LNCaP cells were treated with or without EGCG (50 µM) in the presence of 50 nM R1881 for 18 h. In the absence of R1881, AR was distributed in the cytoplasm and nucleus; however, AR protein was localized in the nucleus with R1881 treatment (Fig. 5B) . Co-treatment with EGCG and R1881 resulted in the inhibition of AR translocation and the retention of AR in the cytoplasm. Thus, EGCG inhibits acetylation-dependent AR translocation, which leads to prostate cancer cell death, particularly in androgen-dependent cells. These results reveal a mechanism by which EGCG, and likely EC and EGC, induces prostate cancer cell death via inhibition of agonist-induced AR translocation through its anti-HAT activity.
Discussion
Several HAT inhibitors derived from natural products (14, 15) have been discovered and found to have potent chemopreventive and therapeutic activities against a wide variety of tumors. Nevertheless, compared to HDAC inhibitors, the antitumor effects of HAT inhibitors have been less well-characterized. We have previously reported that EGCG is an effective HAT inhibitor (9) , which inhibits the acetylation of the RelA (p65) subunit of nuclear factor-κB (NF-κB). Here, we suggest that the green tea catechins EGCG, EGC and EC induce androgen-dependent prostate cancer cell death by inhibiting AR-mediated transcription through their anti-HAT activities.
First, we demonstrated that the relative efficacy of individual green tea catechins in promoting androgen-dependent prostate cancer cell death varies directly with the strength of anti-HAT activity (EGCG > EGC > EC). Interestingly, activity differences among the individual catechins were also detected in reporter assays and measurements of AR-target gene expression. EGCG is one of the most promising growth suppressors for a variety of tumors, including prostate cancer, as has been suggested by numerous researchers (16, 17) . Here, we demonstrate that EGCG can effectively suppress androgen-dependent prostate cancer cell growth and proliferation. Transcription factors, such as AR and ERα, are regulated through acetylation by HATs (7, 8) and there is strong evidence that AR acetylation is involved in the regulation of prostate cell growth, apoptosis and proliferation (13) . Therefore, we examined whether the growth inhibitory effects of EC, EGC and EGCG on androgen-dependent prostate cancer cells are dependent on their anti-HAT activities. We demonstrated that the increased AR acetylation, histone H3 acetylation, and p300 recruitment induced by androgen was significantly suppressed by EGCG treatment. These results were confirmed by transcriptional reporter assays in LNCaP cells expressing the p300. EGCG was able to reduce gene transcription associated with p300 HAT activity to levels comparable to flutamide treatment. This result has a biological significance, because AR antagonists such as flutamide and bicalutamide are broadly used in the treatment of prostate cancer (18) . The functional dependence of flutamide on prostate cancer has been demonstrated in several studies implies that the levels of HDAC or HAT in patients may be a determinant for the efficacy of anti-hormone therapy (19) . Also, EGCG inhibits acetylation-dependent AR translocation in androgen-dependent cells. HAT protein promotes prostate cancer cell proliferation by translocation of AR into the nucleus (20) , and EGCG may suppress prostate cancer by inhibiting this translocation. Siddiqui et al (21) reported that green tea EGCG blunts AR function in prostate cancer. Here, we suggest that EGCG may suppress tanslocation of AR into the nucleus by modulating acetyltion.
In addition, developing drugs with increased capability to inhibit the AR-p300 interaction is likely to improve the efficacy of current anti-hormone therapy. In conclusion, EGCG treatment effectively inhibited agonist-induced AR acetylation, and subsequently, reduced the hormone responsiveness of AR. Therefore, we suggest that the reduction of AR acetylation mediated by EGCG represses androgen signaling and thereby acetylation-dependent prostate cancer cell growth and proliferation. These observations will be useful in the design of clinical trials for HATi-based therapies against prostate cancer.
